

**Claims:**

No amendments to the claims are made herein. A listing of claims is provided for the Examiner's convenience:

**Listing of Claims:**

Claims 1-11 (canceled).

Claim 12 (previously presented): A method of delivering a substance to microtubules, comprising exposing said microtubules to said substance, said substance being in a form selected from the group consisting of a fusion, a covalent coupling and a non-covalent association, of said substance with a protein, wherein said protein is a herpesviral VP22 protein, or is a portion or derivative thereof which has a microtubule binding function of VP22.

Claim 13 (previously presented): A method of preparing a medicament for delivery of a substance to microtubules which comprises fusing, covalently coupling or non-covalently associating said substance for delivery with a herpesviral VP22 protein, or a portion or derivative thereof which has microtubule binding function of VP22, and then formulating the fused, covalently coupled, or non-covalently associated substance with a pharmaceutically acceptable excipient, thereby to form said medicament.

Claim 14 (previously presented): The method of claim 13, wherein the medicament is a coupling product comprising both herpesviral VP22 and a substance to be delivered to microtubules.

Claim 15 (previously presented): The method of claim 13, wherein the substance binds to microtubules.

Claim 16 (previously presented): The method of claim 15, wherein the substance is taxol, or colchicine.